Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
Status:
Recruiting
Trial end date:
2023-09-15
Target enrollment:
Participant gender:
Summary
This study aims to investigate the possible role of rosuvastatin in protection against
cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with
trastuzumab.